Featuring Larry Green, MD Dr. Larry Green presented a new medication for the treatment of psoriasis that will soon be released in the US. Duobrii is a once daily topical emulsion lotion that is FDA approved for the treatment of psoriasis. Dr. Green reports when psoriasis patients are surveyed, 100% have used topical treatments, while …
Featuring Guest Faculty, Douglas DiRuggiero, MHS, PA-C For the Thursday morning product theater, Douglas DiRuggiero, MHS, PA-C, reviewed psoriasis and specifically treatment with the biologic medication Cosentyx. Mr. DiRuggiero emphasized both the effectiveness and safety of Cosentyx in his presentation. There are currently up to 75, 000 patients using Cosentyx, the first and only fully …
Patients with psoriasis are at increased risk of certain cancers and there are questions about the contribution of long-term use of biologic and immune modulatory therapies to the risk factors. A roundtable was convened to look at questions around the association between cancer and psoriasis and to make clinical observations and recommendations based on published …
Patients with psoriasis are at increased risk for other comorbid diseases that involve inflammatory processes. There have been studies that link psoriasis and Crohn’s disease (CD) and ulcerative colitis (UC), two forms of inflammatory bowel disease (IBD). As progress has been made to understand the pathogenesis of both diseases, treatment options have expanded, including using …
Patients with psoriasis are also at increased risk of other conditions, especially diabetes, hypertension, and cardiovascular problems including heart failure. Recent studies have indicated that patients with psoriasis may have alterations and dysfunction in the way the heart works. There are data pointing to impaired left ventricular (LV) deformations which is critical for systolic function …